The Five Systems of Dysphagia: MCI to the AD Spectrum of Disorders

2016 ◽  
Vol 1 (15) ◽  
pp. 37-52
Author(s):  
Jeanna Winchester ◽  
Carol G. Winchester

In order to swallow safely and effectively, there are five bodily systems that must work in coordination: Muscular, Respiratory, Neurological, Cognitive, and Gastrointestinal. Previously, these systems were established as the Five Systems of Dysphagia (5SysDys). Additionally, there exists an array of diseases/disorders that are linked to the development of Alzheimer's disease, and the current perspective proposes that these diseases/disorders can be referred to as the Alzheimer's Spectrum of Disorders (AD Spectrum). The current perspective proposes that the breakdown of the 5SysDys among patients suffering from the AD Spectrum is observable at the amnestic Mild Cognitive Impairment (aMCI) stage. Further, this perspective elucidates this relationship and distinguishes among the AD Spectrum, as well as proposes, for the first time in the literature, what types of 5SysDys breakdown is observable at the aMCI stage; aMCI is subdivided into the single and multiple domain diagnoses (SDaMCI & MDaMCI, respectively). We propose literature-driven conclusions and illustrate the importance of considering effective Dysphagia Management in the aMCI and AD Spectrum populations.

2020 ◽  
Vol 17 ◽  
Author(s):  
Hyung-Ji Kim ◽  
Jae-Hong Lee ◽  
E-nae Cheong ◽  
Sung-Eun Chung ◽  
Sungyang Jo ◽  
...  

Background: Amyloid PET allows for the assessment of amyloid β status in the brain, distinguishing true Alzheimer’s disease from Alzheimer’s disease-mimicking conditions. Around 15–20% of patients with clinically probable Alzheimer’s disease have been found to have no significant Alzheimer’s pathology on amyloid PET. However, a limited number of studies had been conducted this subpopulation in terms of clinical progression. Objective: We investigated the risk factors that could affect the progression to dementia in patients with amyloid-negative amnestic mild cognitive impairment (MCI). Methods: This study was a single-institutional, retrospective cohort study of patients over the age of 50 with amyloidnegative amnestic MCI who visited the memory clinic of Asan Medical Center with a follow-up period of more than 36 months. All participants underwent brain magnetic resonance imaging (MRI), detailed neuropsychological testing, and fluorine-18[F18]-florbetaben amyloid PET. Results: During the follow-up period, 39 of 107 patients progressed to dementia from amnestic MCI. In comparison with the stationary group, the progressed group had a more severe impairment in verbal and visual episodic memory function and hippocampal atrophy, which showed an Alzheimer’s disease-like pattern despite the lack of evidence for significant Alzheimer’s disease pathology. Voxel-based morphometric MRI analysis revealed that the progressed group had a reduced gray matter volume in the bilateral cerebellar cortices, right temporal cortex, and bilateral insular cortices. Conclusion: Considering the lack of evidence of amyloid pathology, clinical progression of these subpopulation may be caused by other neuropathologies such as TDP-43, abnormal tau or alpha synuclein that lead to neurodegeneration independent of amyloid-driven pathway. Further prospective studies incorporating biomarkers of Alzheimer’s diseasemimicking dementia are warranted.


2014 ◽  
Vol 11 (2) ◽  
pp. 200-205
Author(s):  
Aleksandra Klimkowicz-Mrowiec ◽  
Lukasz Krzywoszanski ◽  
Karolina Spisak ◽  
Bryan Donohue ◽  
Andrzej Szczudlik ◽  
...  

PLoS ONE ◽  
2014 ◽  
Vol 9 (8) ◽  
pp. e105623 ◽  
Author(s):  
Katerina Sheardova ◽  
Jan Laczó ◽  
Martin Vyhnalek ◽  
Ross Andel ◽  
Ivana Mokrisova ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document